Novel strategies based on the genetic signature of the tumour lead to promising therapies with androgen receptor (AR)‐targeted drugs, antibody‐drug conjugates (ADC), poly ADP‐ribose polymerase inhibitors (PARPI), or tyrosine kinase inhibitors (TKI) [8, 11, 12, 13]. This evidence concerns the gene AR and neoplasm.